Literature DB >> 23024524

Nifedipine versus ritodrine for suppression of preterm labor and analysis of side effects.

Purushottam Bankatlal Jaju1, Veena B Dhabadi.   

Abstract

OBJECTIVES: To compare the tocolytic efficacy of Nifedipine and Ritodrine, their adverse effects and neonatal outcome.
DESIGN: Prospective randomized trial.
METHODS: One hundred twenty women with clinical features of preterm labor fulfilling designated inclusion and exclusion criteria were enrolled in the study. They were allocated to either nifedipine group or Ritodrine group by using simple randomization technique. Tocolytic efficacy, maternal side effects and neonatal outcomes were evaluated. Tools of statistical analysis used were Epi Info software and Chi square test.
RESULTS: Tocolysis was successful i.e., prolongation of pregnancy for 48 h in 54 (90%) women in Nifedipine group as compared to 41 (68.3%) women in Ritodrine group (P value = 0.003 and χ(2) = 8.54). The prolongation of pregnancy up to 37 weeks was observed in 28 women (46.6%) in Nifedipine group compared to 16 women (26.6%) in Ritodrine group (P value = 0.033). 18 women (30%) in Nifedipine group had side effects compared to 48 women (80%) in Ritodrine group (P value < 0.001). Neonatal outcome was similar in both the groups.
CONCLUSION: Oral Nifedipine is cheaper and effective alternative which has fewer and less serious side effects as compared to I.V. Ritodrine for suppression of the preterm labor.

Entities:  

Keywords:  Nifedipine; Preterm labor; Ritodrine; Tocolysis

Year:  2011        PMID: 23024524      PMCID: PMC3257333          DOI: 10.1007/s13224-011-0083-y

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  6 in total

1.  A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome.

Authors:  J E Ferguson; D C Dyson; T Schutz; D K Stevenson
Journal:  Am J Obstet Gynecol       Date:  1990-07       Impact factor: 8.661

2.  Atosiban and nifedipin for the treatment of preterm labor.

Authors:  M Kashanian; A R Akbarian; M Soltanzadeh
Journal:  Int J Gynaecol Obstet       Date:  2005-10       Impact factor: 3.561

3.  Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial.

Authors:  D N Papatsonis; H P Van Geijn; H J Adèr; F M Lange; O P Bleker; G A Dekker
Journal:  Obstet Gynecol       Date:  1997-08       Impact factor: 7.661

4.  Nifedipine versus ritodrine for suppression of preterm labour.

Authors:  M Kupferminc; J B Lessing; Y Yaron; M R Peyser
Journal:  Br J Obstet Gynaecol       Date:  1993-12

5.  Nifedipine versus ritodrine for suppressing preterm labor.

Authors:  W R Meyer; H W Randall; W L Graves
Journal:  J Reprod Med       Date:  1990-06       Impact factor: 0.142

6.  The use of a calcium antagonist (nifedipine) to suppress preterm labour.

Authors:  M D Read; D E Wellby
Journal:  Br J Obstet Gynaecol       Date:  1986-09
  6 in total
  4 in total

1.  Sulfation of ritodrine by the human cytosolic sulfotransferases (SULTs): Effects of SULT1A3 genetic polymorphism.

Authors:  Ying Hui; Ming-Cheh Liu
Journal:  Eur J Pharmacol       Date:  2015-05-02       Impact factor: 4.432

Review 2.  Calcium channel blockers for inhibiting preterm labour and birth.

Authors:  Vicki Flenady; Aleena M Wojcieszek; Dimitri N M Papatsonis; Owen M Stock; Linda Murray; Luke A Jardine; Bruno Carbonne
Journal:  Cochrane Database Syst Rev       Date:  2014-06-05

Review 3.  Tocolytics for delaying preterm birth: a network meta-analysis (0924).

Authors:  Amie Wilson; Victoria A Hodgetts-Morton; Ella J Marson; Alexandra D Markland; Eva Larkai; Argyro Papadopoulou; Arri Coomarasamy; Aurelio Tobias; Doris Chou; Olufemi T Oladapo; Malcolm J Price; Katie Morris; Ioannis D Gallos
Journal:  Cochrane Database Syst Rev       Date:  2022-08-10

4.  Calcium channel blockers as tocolytics: principles of their actions, adverse effects and therapeutic combinations.

Authors:  Róbert Gáspár; Judit Hajagos-Tóth
Journal:  Pharmaceuticals (Basel)       Date:  2013-05-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.